The 2015 guidelines for idiopathic pulmonary fibrosis: an important chapter in the evolution of the management of patients with IPF
Authors:
Open Access
- 30 September 2015
- journal article
- editorial
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 46 (4) , 883-886
Abstract
2015 guidelines for treatment of IPF empowers the clinician and patient to make individualised treatment decisions http://ow.ly/R37nzKeywords
This publication has 12 references indexed in Scilit:
- An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis: An Update of the 2011 Clinical Practice GuidelineAmerican Journal of Respiratory and Critical Care Medicine, 2015
- Efficacy and Safety of Nintedanib in Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2014
- Prednisone, Azathioprine, andN-Acetylcysteine for Pulmonary FibrosisNew England Journal of Medicine, 2012
- Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary FibrosisNew England Journal of Medicine, 2011
- Clinical Practice Guidelines We Can Trust2011
- Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trialsThe Lancet, 2011
- An Official ATS/ERS/JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and ManagementAmerican Journal of Respiratory and Critical Care Medicine, 2011
- Pirfenidone in idiopathic pulmonary fibrosisEuropean Respiratory Journal, 2009
- Double-blind, Placebo-controlled Trial of Pirfenidone in Patients with Idiopathic Pulmonary FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2005
- Idiopathic Pulmonary Fibrosis: Diagnosis and Treatment: International Consensus StatementAmerican Journal of Respiratory and Critical Care Medicine, 2000